2025-10-17 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the data you provided, formatted for an English-language report with a focus on key numbers and analysis.

## TransMedics Group Inc. (TMDX) Analysis

TransMedics Group Inc. is a medical technology company focused on preserving organ viability for transplantation.

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 178.61%
*   **VOO Cumulative Return:** 71.67%
*   **Absolute Divergence (Current):** 97.1
*   **Relative Divergence (Current):** 53.3

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the period. The current cumulative return difference is substantial. The relative divergence of 53.3 indicates that TMDX's outperformance, while still positive, is not at the extreme upper end of its historical range.  It's important to remember that relative divergence is a measure of historical range, not necessarily a predictor of future performance.

**Alpha, Beta Analysis**

| Year       |   CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|:-----------|-------:|------:|--------:|-------:|---------:|
| 2019-2021  |   -18  |  83.5 |    -61  |   -0   |      0.7 |
| 2020-2022  |    94  |  83.5 |     95  |    0   |      2.2 |
| 2021-2023  |    65  |  80.5 |     64  |    0.1 |      2.8 |
| 2022-2024  |   130  |  85.5 |    109  |    0.1 |      2.2 |
| 2023-2025  |    99  |  85.5 |     38  |    0.3 |      3.9 |

*   **CAGR:** The Compound Annual Growth Rate shows strong growth in recent periods (2020-2025), after a weaker 2019-2021 period.
*   **MDD:**  The Maximum Drawdown is consistently high, indicating significant volatility and risk.
*   **Alpha:**  Alpha is generally positive, suggesting TMDX has generated returns above what would be expected based on market movements alone.  The alpha is particularly high in the 2020-2024 periods. But 2023-2025 is lower alpha.
*   **Beta:** Beta is generally low, suggesting TMDX's price movements are not highly correlated with the overall market.
*   **Cap(B):** Market capitalization has grown over time.

### 2. Recent Stock Price Movement

*   **Current Price:** 111.23
*   **Last Market Data:** Price: 115.68, Previous Close: 112.61, Change: 2.73
*   **5-day Moving Average:** 111.33
*   **20-day Moving Average:** 115.39
*   **60-day Moving Average:** 115.76

**Analysis:** The current price (111.23) is below all the moving averages, indicating a potential short-term downtrend.  The recent market data shows a positive change (2.73 increase), suggesting a potential rebound or consolidation.

### 3. Technical Indicators and Outlook

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 40.01
*   **PPO:** -0.46
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (8 shares - Very Safe - MRI:0.90)
*   **Delta_Previous_Relative_Divergence:** -6.2 (Decreasing, short-term decline)
*   **Expected Return:** 63.0% (Over S&P 500, long-term, 2+ years)

**Analysis:**

*   **MRI:**  The Medium Investment recommendation suggests moderate risk-adjusted investment appropriateness.
*   **RSI:** The RSI of 40.01 is below 50 and approaching oversold territory, suggesting a potential buying opportunity.
*   **PPO:** The negative PPO indicates a downtrend in price momentum.
*   **Hybrid Signal:** The signal indicates a "Buy" recommendation, allocating 100% of available cash, and considers it a "Very Safe" investment given the MRI.
*   **Delta_Previous_Relative_Divergence:** The negative change in relative divergence suggests short-term underperformance relative to the S&P 500.
*   **Expected Return:** The high expected return (63% above S&P 500) suggests a bullish long-term outlook, despite the short-term headwinds.

### 4. Recent News & Significant Events (Yahoo Finance)

*   **[2025-10-15]** TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025
*   **[2025-10-14]** TransMedics Group Stock Earns Relative Strength Rating Upgrade
*   **[2025-10-13]** Jefferies Initiates TransMedics Group at Buy With $145 Price Target
*   **[2025-10-09]** There's Been No Shortage Of Growth Recently For TransMedics Group's (NASDAQ:TMDX) Returns On Capital
*   **[2025-10-08]** 2 Outstanding Healthcare Stocks to Buy and Hold for a Decade
*   **[2025-09-24]** Here's Why TransMedics (TMDX) is a Strong Growth Stock

**Analysis:** Recent news is predominantly positive. Analyst upgrades, "Buy" initiations with price targets above the current price, and articles highlighting growth and long-term potential paint a favorable picture. The upcoming earnings report on October 29th is a key event to watch.

#### 4.2 Analyst Opinions

*   **Consensus:** Buy (~1.75 on scale)
*   **Opinions:** 10
*   **Target Price (avg/high/low):** 141.00 / 170.00 / 114.00
*   **Recent Rating Changes:**  No specific changes were listed, which could indicate stable analyst sentiment.

**Analysis:** Analyst consensus is strongly bullish, with a "Buy" rating and an average price target of $141.00, significantly above the current price.

### 5. Recent Earnings Analysis

| 날짜       |   EPS |   예상 EPS |
|:-----------|------:|-----------:|
| 2025-07-30 |  0.92 |       0.48 |
| 2025-05-08 |  0.7  |       0.29 |
| 2025-02-27 |  0.19 |       0.22 |
| 2024-10-28 |  0.12 |       0.29 |
| 2024-07-31 |  0.35 |       0.21 |

**Analysis:** TransMedics has consistently exceeded EPS expectations in recent quarters, especially in the most recent two quarters. This positive earnings surprise likely contributes to the positive analyst sentiment and overall bullish outlook.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    |   Revenue |   Profit Margin |
|:-----------|----------:|----------------:|
| 2025-06-30 |      0.16 |           61.38 |
| 2025-03-31 |      0.14 |           61.47 |
| 2024-12-31 |      0.12 |           59.21 |
| 2024-09-30 |      0.11 |           55.94 |
| 2024-06-30 |      0.11 |           60.59 |

**Capital and Profitability:**

| Quarter    |   Equity |     ROE |
|:-----------|---------:|--------:|
| 2025-06-30 |     0.32 |   10.97 |
| 2025-03-31 |     0.27 |    9.64 |
| 2024-12-31 |     0.23 |    3    |
| 2024-09-30 |     0.21 |    2.01 |
| 2024-06-30 |     0.19 |    6.42 |

**Analysis:**

*   **Revenue:** Revenue is consistently increasing quarter over quarter, indicating strong top-line growth.
*   **Profit Margin:** Profit margins are very high and relatively stable, suggesting strong pricing power and efficient operations.
*   **Equity:** Equity is increasing, indicating a strengthening balance sheet.
*   **ROE:** Return on Equity has shown improvement in the most recent quarters.

### 7. Overall Summary and Conclusion

TransMedics (TMDX) presents a compelling investment case based on the provided data. Key highlights include:

*   **Significant Outperformance:**  TMDX has substantially outperformed the S&P 500, although recent relative performance has cooled slightly.
*   **Strong Growth:** Revenue and earnings are growing rapidly, and the company has consistently exceeded EPS expectations.
*   **High Profitability:**  Profit margins are exceptionally high.
*   **Positive Analyst Sentiment:** Analysts are overwhelmingly bullish, with "Buy" ratings and significant upside potential based on target prices.
*   **Positive News Flow:** Recent news articles highlight growth, potential, and analyst recognition.
*   **Medium Risk:** The Market Risk Indicator (MRI) indicates that the stock carries a medium level of risk.
*   **Short-Term Downtrend:** Recent price action and technical indicators suggest a possible short-term downtrend, potentially creating a buying opportunity.
*   **Long-Term Potential:** The high expected return and analyst consensus suggest substantial long-term upside potential.

**In conclusion,** while a short-term pullback is possible, TransMedics appears to be a strong growth stock with significant long-term potential. Investors should carefully consider their risk tolerance and conduct further due diligence before making any investment decisions. The upcoming earnings report on October 29th will be a critical event to monitor.
